|
Dose and duration of analgesic use and risk of ESRD: All analgesics. |
|||||
| Short duration |
Long Duration |
||||
|
|
|||||
| Cases/controls |
OR (95% CI)* |
Cases/controls |
OR (95% CI) * |
||
|
|
|||||
| Low dose |
All analgesics |
123/580 |
0.78 (0.63–0.97) |
36/216 |
0.62 (0.43–0.89) |
| All monos together1 |
106/529 |
0.74 (0.59–0.93) |
31/200 |
0.57 (0.39–0.85) |
|
| All combis together2 |
49/264 |
0.69 (0.50–0.95) |
19/84 |
0.84 (0.51–1.40) |
|
| High Dose |
All analgesics |
70/214 |
1.21 (0.91–1.61) |
132/582 |
0.84(0.67–1.05) |
| All monos together1 |
60/194 |
1.14 (0.84–1.55) |
117/531 |
0.82(0.65–1.03) |
|
| All combis together2 |
29/88 |
1.22 (0.79–1.88) |
71/268 |
0.99 (0.74–1.33) |
|
|
1 Cases and controls that never used mono-analgesics were not shown in this table (47 cases, 138 controls for the group "all monos" 2 Cases and controls that never used combination-analgesics were not shown in this table (193 cases, 888 controls for the group "all combis" Unmatched analysis; index date 3 (5 years before start of dialysis); adjusted odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age, sex, country. The cut-off point for higher/lower use and shorter/longer duration is the respective median found in controls; compared with the standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) as referent (= 1.0): 546 cases and 2030 controls. | |||||
van der Woude et al. BMC Nephrology 2007 8:15 doi:10.1186/1471-2369-8-15 |
|||||